Cerebrovascular disease in young patients

Thrombosis and Haemostasis

Volumn 78, Issue 1, 1997, Pages 13-23

  Grotta, James ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

AGE; BLOOD CLOT LYSIS; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; NEUROPROTECTION; PRIORITY JOURNAL; REHABILITATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030745166     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1657494     Document Type: Conference Paper

References (151)

1. Grotta JC. Current medical and surgical therapy for cerebrovascular disease. New Engl J Med 1987; 317: 1505-1516.
2. Adams HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Stroke 1993; 24: 35-41.
3. Dusser A, Goutieres G, Aicardi H. Ischemic strokes in children. J Child Neurol 1: 131, 1986.
4. Barmada MA, Moosy J, Shuman RM. Cerebral infarcts with arterial occlusion in neonates. Ann Neurol 6: 495, 1979.
5. Levene M. Current Reviews in Paediatrics. Neonatal Neurology : Vol 3. Churchill Livingstone, New York, 1987.
6. Lanska MJ, Lanska DJ, Horwitz SJ, Aram DM. Presentation, clinical course, and outcome of childhood stroke. Pediatr Neurol 7: 333, 1991.
7. Roessman U, Miller RT. Thrombosis of the middle cerebral artery associated with birth trauma. Neurology 30: 889, 1980.
8. Jackson AC, Boughner DR, Barnett HJM. Mitral valve prolapse and cerebral ischemic events in young patients. Neurology 34: 784, 1984.
9. Packer RJ, Rorke LB, Lange BJ et al. Cerebrovascular accidents in children with cancer. Pediatrics 76: 194, 1985.
10. Huttenlocher PR, Mohr JW, Johns L. Cerebral blood flow in sickle cell cerebrovascular disease. Pediatrics 73: 615, 1984.
11. Pavlakis SG, Phillips PC, Di Mauro S et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol 16: 481, 1984.
12. Whisnant, JP. Effectiveness versus efficacy of treatment of hypertension for stroke prevention. Neurology 1996; 46: 301-307.
13. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin survival study (4S). The Lancet 1994; 344: 1383-1389.
14. Bronner LL, Kanter DS and Manson JE. Primary prevention of stroke. New Engl J Med 1995; 333: 1392-1399.
15. Levine SR, Brust JCM, Futrell N et al. A comparative study of the cerebrovascular complications of cocaine: Alkaloidal versus hydrochloride - a review. Neurology 1991; 41: 1173-1177.
16. Gorelick PB. Stroke prevention: An opportunity for efficient utilization of health care resources during the coming decade. Stroke 1994; 25: 220-224.
17. Howard G, Anderson R, Sorlie P et al. Ethnic differences in stroke mortality between non-Hispanic whites, Hispanic whites and blacks. Stroke 1994; 25: 2120-2125.
18. Morgenstern LB, Spears WD, Goff DC et al. African Americans and women have the highest stroke mortality in Texas. Stroke 1997; (in press).
19. Clarke R, Kaly L, Robinson K et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. New Engl J Med 1991; 324: 1149-1155.
20. Schievink WI, Michels VV and Piepgras DG. Neurovascular manifestations of heritable connective tissue disorders. A review. Stroke 1994; 25: 889-903.
21. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. New Engl J Med 1991; 325: 445-452.
22. European Carotid Surgery Trialists' Collaborative Group. Endarterectomy for moderate symptomatic carotid stenosis: Interim results from the MRC European Carotid Surgery Trial. The Lancet 1991; 337: 1235-43.
23. Eliasziw M, Streifler JY, Fox AJ et al. Significance of plaque ulceration in symptomatic patients with high-grade carotid stenosis. Stroke 1994; 25: 304-308.
24. Executive Committee of the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995; 273: 1421-1428.
25. Hobson RW, Weiss DG, Fields WS et al. Efficacy of carotid endarterectomy for asymptomatic carotid stenosis. New Engl J Med 1993; 328: 221-228.
26. The CASANOVA Study Group. Carotid surgery versus medical therapy in asymptomatic carotid stenosis. Stroke 1991; 22: 1229-1235.
27. Higashida RT, Tsai FY, Halbach VV et al. Transluminal angioplasty for atherosclerotic disease of the vertebral and basilar arteries. J. Neurosurg. 1993; 78: 192-198.
28. Yadav JS, Roubin GS, King P et al. Angioplasty and stenting for restenosis after carotid endarterectomy. Initial Experience. Stroke 1996; 27: 2075-2079.
29. Brown MM for the CAVATAS Investigators. Carotid and vertebral artery transluminal angioplasty study (CAVATAS) progress report. Cerebrovasc. Dis. 1996; 6 (suppl 2): 34.
30. Cerebral Embolism Task Force. Cariogenic brain embolism. The second report of the cerebral embolism task force. Arch. Neurol. 1989; 46: 727-743.
31. Hart RG, Halperin JL. Atrial fibrillation and stroke. Revisiting the dilemmas. Editorial. Stroke 1994; 25: 1337-1341.
32. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch. Intern. Med. 1994; 154: 1449-1457.
33. Stoke Prevention in Atrial Fibrillation Investigators. The stroke prevention in atrial fibrillation study. Final results. Circulation 1991; 84: 527-539.
34. Ezekowits MD, Bridgers SL, Kenneth JE et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. New Engl J Med 1992; 327: 1406-1412.
35. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. New Engl J Med 1990; 323: 1505-1511.
36. The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. New Engl J Med 1995; 333: 5-10.
37. Barnett HJM, Eliasziw M and Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. New Engl J Med 1995; 332: 238-248.
38. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
39. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing physicians' health study. New Engl J Med 1989; 321: 129-135.
40. Peto R, Gray R, Collins R, et al. Randomized trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296: 313-316.
41. Manson JE, Stampfer MJ, Golditz G, et al. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA 1991; 266: 521-527.
42. Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. New Engl J Med 1989; 321: 501-508.
43. Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of Antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. New Engl J Med 1996; 334:1084-1128.
44. CAPRI Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events. The Lancet 1996; 348: 1329-1339.
45. Chimowitz MI, Kokkinos J, Strong J, et al. The warfarin-aspirin symptomatic intracranial disease study. Neurology 1995; 45: 1488-1493.
46. SPIRIT Study Group. Bleeding complications in patients after cerebral ischemia treated with anticoagulant drugs. Cerebrovas Dis 1996; 6 (suppl 2): 77.
47. Astrup J, Symon L, Siesjö BK. Thresholds in cerebral ischemia - the ischemic penumbr̀6 Strojm 1981; 12: 5@C-725.
48. Hossmann KA, Mid G, Paschen W, et al. Multiparametric imaging blood flow and metabolism after middle cerebral artery occlusion in cats. J Cereb Blood Flow Metab 1985; 5; 97-107.
49. Heiss WD, Huber M, Fink GR, et al. Progressive derangement of periinfarct viable tissue in ischemic stroke. J Cereb Blood Flow Metab 1992; 12: 193-203.
50. Hossmann KA. Viability thresholds and the penumbra of focal ischemia. Ann Neurol 1994; 36; 557-565.
51. Lassen AN, Fieschi C, Lenzi GL. Ischemia penumbra and neuronal death: Comments on the therapeutic window in acute stroke with particular reference to thrombolytic therapy. Cerebrovas Dis 1991; 1 (suppl 1): 32-35.
52. Kaplan B, Brint S, Tanabe J, et al. Temporal thresholds for neocortical infarction in rats subjected to reversible focal cerebral ischemia. Stroke 1991; 22: 1032-1039.
53. Jones TH, Morawetz RB, Crowell RM, et al. Thresholds of focal cerebral ischemia in awake monkeys. J Neurosurg 1981; 54: 773-782.
54. Grotta J: Rodent models of acute stroke - limitations. What have we learned from recent clinical trials of thrombolysis? Arch Neurol 1996; 53: 1067-1070.
55. Raichle ME: The pathophysiology of brain ischemia. Ann Neurol 1983; 13: 2-10.
56. Wielock T, Harris RJ, Siesjö BK. Brain metabolism and ischemia: mechanism of cell damage and principals of protection. J Cereb Blood Flow Metab 1982; 2 (suppl 1): S5-S9.
57. Rothman S, Olney J. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 1986; 19: 105-111.
58. DeGraba T, Ostrow P, Grotta J. Threshold of calcium disturbances after focal cerebral ischemia in rats - implications of the window of therapeutic opportunity. Stroke 1993; 24: 1212-1217.
59. Matsushima K, Schmidt-Kastner R, Hakim AM. Genes and cerebral ischemia: Therapeutic perspectives. Cerebrovas Dis 1996; 6: 119-127.
60. Feldmann E, Gordon N, Brooks J, et al. Factors associated with early presentation of acute stroke. Stroke 1993; 24: 1805-1810.61
61. Bratina P, Greenberg L, Pasteur W, Grotta J. Current emergency department management of stroke in Houston, Texas. Stroke 1995; 26: 409-414.
62. Kothari RU, Brott T, Broderick JP, et al. Emergency physicians accuracy in the diagnosis of stroke. Stroke 1995; 26: 2238-2241.
63. Pulsinelli WA, Levy DE, Sigsbee B, et al. Increased damage after ischemic stroke in patients with hyperglycemia with or without established diabetes. Am J Med 1983; 74: 540-544.
64. Grotta JC, Pettigrew LC, Allen S, et al. Baseline menodynamic state and response to hemodilution in patients with acute cerebral ischemia. Stroke 1985; 16: 790-795.
65. The Hemodilution in Stroke Study Group: Hypervolemic hemodilution treatment of acute stroke: results of a randomized multicenter trial using pentastarch. Stroke 1989; 20: 317-323.
66. Wallace JD, Levy LL. Blood pressure after stroke. JAMA 1981; 246: 2177-2180.
67. Strandgaard S, Paulson OB. Cerebral blood flow and its pathophysiology. Am J Hypertension 1989; 2: 486-492.
68. Lisk DR, Grotta JC, Lamik LM, et al. Should hypertension be treated after acute stroke? A randomized controlled trial using single photon emission computed tomography. Arch Neurol 1993; 50: 855-862.
69. Busto R, Globus M, Dietrich D, et al. Effect of mild hypothermia on ischemia-induced release of neurotransmitter and free fatty acids in rat brain. Stroke 1989; 20: 904-910.
70. Reith J, Jorgensen HS, Pedersen PM, et al. Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome. The Lancet 1996; 347: 422-425.
71. Naritomi H, Shimizu T, Oe H, et al. Mild hypothermia therapy in acute embolic stroke: a pilot study. J Stroke and Cerbrovasc Dis 1996; 6 (suppl 1): 193-196.
72. Clifton GL, Allen S, Barrodale P, et al. A phase II study of moderate hypothermia in severe brain injury. Journal of Neurotrauma 1993; 10: 263-271.
73. Duke RJ, Blocj RF, Turpie AG, et al. Intravenous heparin for the prevention of stroke progression in acute partial stable stroke. Ann Int Med 1986; 105: 825-828.
74. Toni D, Fiorelli M, Bastianello S, et al. Hemorrhagic transformation of brain infarct: predictability in the first 5 hours from stroke onset and influence on clinical outcome. Neurology 1996; 46: 341-345.
75. Kay R, Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. New Engl J Med 1995; 333: 1588-1593.
76. The International Stroke Trial Collaborative Group. The international stroke trial. Preliminary results, part 1: Effects of aspirin and heparin separately and in combination. Cerebrovasc Dis 1996; 6 (suppl 2): 23.
77. Chen ZM, Xie JX, Peto R, et al. Chinese acute stroke trial (CAST): Rationale, design and progress. Cerebrovasc Dis 1996; 6 (suppl 2): 23.
78. Candelise L, Motto C, Aritzu E, et al. Aspirin given within 6 hours reduces long term case fatality but not stroke related disability. Cerebrovasc Dis 1996; 6 (suppl 2): 23-24.
79. Adams HP, Brott TG, Furlan AJ. Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the stroke council, American Heart Association. Circulation 1996; 94: 1167-1174.
80. American Heart Association Quality Standards Subcommittee. Practice Advisory: Thrombolytic therapy for acute ischemic stroke - summary statement. Neurology 1996, 47: 835-839.
81. The National Institute of Neurological Disorders and Stroke rt-tPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. New Engl J Med 1995; 333: 1581-1587.
82. Multicentre Acute Stroke Trial - Italy (MAST-1) Group. Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke. The Lancet 1995; 346: 1509-1515.
83. The Multicenter Acute Stroke Trial - Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. New Engl J Med 1996; 335: 145-150.
84. Donnan GA, Davis SM, Chambers BR, et al. Trials of streptokinase in severe acute ischemic stroke. The Lancet 1995; 345: 578-579.
85. The European Cooperative Acute Stroke Study (ECASS). Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. JAMA 1995; 274: 1017-1025.
86. Fletcher AP, Alkjaersig N, Lewis M, et al. A pilot study of urokinase therapy in cerebral infarction. Stroke 1976; 7: 135-142.
87. Meyer JS, Gilroy J, Barnhart J. Therapeutic thrombolysis in cerebral thromboembolism: randomized evaluation of intravenous streptokinase. In Sickert W. Whisnant JP eds. Cerebral Vascular Diseases. New York: Grune & Stratton, 1965: 200-213.
88. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. New Engl J Med 1993; 329: 673-682.
89. Sussman BJ, Fitch TSP. Thrombolysis with fibrinolysin in cerebral arterial occlusion. JAMA 1958; 167: 1705-1709.
90. Brott TG, Haley EC, Levy DE, et al. Urgent therapy for stroke I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992; 23: 632-640.
91. Haley EC, Levy DE, Brott TG et al. Urgent therapy for stroke. II. Pilot study of tissue plasminogen activator administered 91-180 minutes from onset. Stroke 1992; 23: 641-645.
92. Haley EC, Brott TG, Sheppard GL, et al. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. Stroke 1993; 24: 1000-1004.
93. Mori E, Yoneda Y, Tabuchi M, et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992; 42: 976-982.
94. The Japanese Thrombolysis Study Group. Intravenous tissue plasminogen activator in acute thromboembolic stroke: A placebo-controlled, double-blind trial. In G.J del Zoppo, E. Mori, W. Hacke eds. Thrombolytic Therapy in Acute Ischemic Stroke II. Berlin Heidelberg; Springer-Verlag, 1993: 59-65.
95. del Zoppo GJ, Poeck K, Pessin MS, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992; 32: 78-86.
96. Fagan S, Morgenstern L, Petita A, et al. rtPA reduces length of stay and improves disposition following stroke. Stroke (in press).
97. del Zoppo GJ, Higashida RT, Furlan AJ, et al. The prolyse in acute cerebral thromboembolism trial (PROACT): results of 6 mg dose tier. Stroke 1996; 27: 164.
98. The Ancrod Stroke Study Investigators. Ancrod for the treatment of acute ischemic brain infarction. Stroke 1994; 25: 1755-1759.
99. Allen GS, Ahn HS, Preziosi TJ, et al. Cerebral arterial spasm - a controlled trial of nimodipine in patients with subarachnoid hemorrhage. New Engl J Med 1983; 308: 619-624.
100. Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimidipine on cerebral infarction and outcome after subarachnoid hemorrhage: British Aneurysm Nimodipine Trial. Brit Med J 1989; 298: 636-642.
101. The American Nimodipine Study Group. Clinical trial of nimodipine in acute ischemic stroke. Stroke 1992; 22: 3-8.
102. Mohr JP, Orgogozo J, Harrison M, et al. Meta-analysis of oral nimodipine trials in acute ischemic stroke. Cerebrovasc Dis 1994; 4: 197-203.
103. The Lubeluzole International Study Group. Lubeluzole in acute ischemic stroke: a double-blind, placebo-controlled phase II trial. Stroke 1996; 27: 76-81.
104. The LUB-INT-9 Lubeluzole Study Group. The efficacy and safety of Lubeluzole in patients with acute ischemic stroke. Stroke 1996 (in press).
105. Grotta JC, Clark W, Coull B, et al. Safety and tolerability of the glutamate antagonist CGS 19755 (selfotel) in patients with acute ischemic stroke. Results of a phase IIa randomized trial. Stroke 1995; 26: 602-605.
106. Albers, GW, Atkinson RP, Kelley RE, et al. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrophan in patients with acute stroke. Stroke 1995; 26: 254-258.
107. 107.The CNS 1102-008 Study Group. Cerestat (aptiganel hydrochloride) in the treatment of acute ischemic stroke: results of a phase II trial. Neurology 1996; 46: A424.
108. Clark WM, Coull BM, Karukin M, et al. Randomized trial of cervene, a K receptor-selective opioid antagonist, in acute ischemic stroke. Stroke and Cerebrovasc Dis 1996; 6: 35-40.
109. Tietjen GE, Dombi T, Pulsinelli WA, et al. A double-blind, safety and tolerance study of single intravenous doses of fosphenytoin in patients with acute ischemic stroke. Neurology 1996; 46: A424.
110. Yang G, Betz L. Reperfusion-induced injury to the blood-brain barrier after middle cerebral artery occlusion in rats. Stroke 1994; 25: 1658-1665.
111. Kassell NF, Haley EC, Hansen C, et al. Randomized, double-blind, vehicle controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: A cooperative study in Europe, Australia, and New Zealand. J. Neurosurg 1996; 84: 221-228.
112. The RANTTAS Investigators. A randomized trial of tirilazad mesylate in patients with acute stroke. Stroke 1996; 27: 1455-1458.
113. Sariano SG, Lipton SA, Wang YF, et al. Intercellular adhesion molecule-1-deficient mice are less susceptible to cerebral ischemia-Reperfusion injury. Ann Neurol 1996; 39: 618-624.
114. Kirschner PB, Henshaw R, Weise J, et al. Basic fibroblast growth factor protects against excitotoxicity and chemical hypoxia in both neonatal and adult rats. J Cereb Blood Flow Metab 1995; 15: 619-623.
115. Clark WM and Warach SJ. Randomized dose response trial of citicoline in acute ischemic stroke patients. Neurology 1996; 46: A425.
116. Heros RC. Surgical treatment of cerebellar infarction. Stroke 1992; 23: 937-938.
117. Forsting M, Reith W, Schabitz WR, et al. Decompressive craniectomy for cerebral infarction. An experimental study in rats. Stroke 1995; 26: 259-264.
118. Rieke K, Schwab St, Krieger D, et al. Decompressive surgery in space-occupying hemispheric infarction: results of an open, prospective trial. Critical Care Medicine 1995; 23: 1576-1587.
119. Jorgensen HS, Nakayama H, Rasschou HO, et al. The effect of a stroke unit: Reductions in mortality, discharge rate to nursing home, length of hospital stay, and cost. A community-based study. Stroke 1995; 26: 1178-1182.
120. Wentworth DA and Atkinson RP. Implementation of an acute stroke program decreases hospitalization costs and length of stay. Stroke 1996; 27: 1040-1043.
121. Mitchell J, Bollard D, Whisnant J, Ammering C, Samsa G, Matchar D. What role do neurologists play in determining the costs and outcomes of stroke patients? Stroke 1996; 27: 1937-1943.
122. Kalra L. The influence of stroke unit rehabilitation on functional recovery from stroke. Stroke 1994; 25: 821-825.
123. Karbe H, Thiel A, Weber-Luxemburger G, et al. Post-stroke aphasia: How does the brain cope with the functional impairment. Cerebrovasc Dis 1996; 6 (suppl 2): 17.
124. Frackowiak RSJ. Plasticity and the human brain: insights from functional imaging. Neuroscientist 1996; 2: 353-362.
125. Nudo RJ, Wise BM, SiFuentes, et al. Neural substrates for the effects of rehabilitative training on motor recovery after ischemic infarct. Science 1996; 272: 1791-1794.
126. Koslowski DA, James DC, Schallert T. Use-dependent exaggeration of neuronal injury after unilateral sensorimotor cortex lesions. J Neuroscience 1996; 16: 4776-4786.
127. Johansson K, Lindgren I, Widner H, et al. Can sensory stimulation improve the functional outcome in stroke patients? Neurology 1993; 43: 2189-2192.
128. Walker-Batson D, Smith P, Curtis S, et al. Amphetamine paired with physical therapy accelerates motor recovery after stroke. Further evidence. Stroke 1995; 26: 2254-2259.
129. Bhakta BB, Cozens JA, Bamford JM, et al. Use of botulinum toxin in stroke patients with severe upper limb spasticity. JNNP 1996; 61: 30-35.
130. Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996; 46: 1306-1310.
131. Penn RD, Savoy SM, Corcos D, et al. Intrathecal baclofen for severe spinal spasticity. New Engl J Med 1989; 320: 1517-1521.
132. Awad IA, Carter LP, Spetzler RF, et al. Clinical vasospasm after subarachnoid hemorrhage: response to hypervolemic hemodilution and arterial hypertension. Stroke 1987; 18:365-372.
133. Guglielmi G, Vinuela F, Sepetka E, et al. Electrothrombosis of saccular aneurysms via endovascular approach. Part 1. electrochemical basis, technique, and experimental results. J Neurosurg 1991; 75: 1-7.
134. Guglielmi G, Vinuela F, Dion J, et al. Electrothrombosis of saccular aneurysms via endovascular approach. Part 2. preliminary clinical experience. J Neurosurg 1991; 75: 8-14.
135. Casaco AE, Aymard A, Gobin YP, et al. Selective endovascular treatment of 71 intracranial aneurysms with platinum coils. J Neurosurg 1993; 79: 3-10.
136. Guglielmi G, Vinuela F, Duckwiler, G, et al. Endovascular treatment of posterior circulation aneurysms by electrothrombosis using electrically detachable coils. J Neurosurg 1992; 77: 515-524.
137. Lunsford LD, Kondziolka D, Flickinger JC, et al. Sterotactic radiosurgery for arteriovenous malformations of the brain. J Neurosurg 1991; 75: 512-524.
138. Broderick J, Brott T, Tomskick T, et al. Management of intracerebral hemorrhage in a large metropolitan population. Neurosurgery 1994; 34: 882-887.
139. Kaneko J, Tanaka K, Shimada T, et al. Long term evaluation of ultra-early operation for hypertensive intracerebral hemorrhage in 100 cases. J Neurosurg 1983; 58:838-842.
140. Niizuma H, Shimuzu Y, Yonemitsu T, et al. results of stereotactic aspiration in cases of putaminal hemorrhage. Neurosurg 1989; 24: 814-819.
141. Auer L, Deinsberger W, Niederkorn K, et al. Endoscopic surgery vs. medical treatment for spontaneous intracerebral hematoma: a randomized study. J Neurosurg 1989; 70: 530-535.
142. Juvela S, Heiskanes O, Proanen A, et al. The treatment of spontaneous intracerebral hemorrhage. A prospective randomized trial of surgical and conservative treatment. J Neurosurg 1989; 70: 755-758.
143. Batjer H, Reisch J, Allen B, et al. Failure of surgery to improve outcome in hypertensive putaminal hemorrhage. A prospective randomized trial. Arch Neurol 1990; 47: 1103-1106.
144. Kandel EI, Peresedov VV. Stereotaxic evacuation of spontaneous intracerebral hematomas. J Neurosurg 1990; 54: 427-431.
145. Grotta J, Morgenstern L, Shedden P, et al. Randomized trial of early surgery for hemispheric intracerebral hemorrhage. Cerebrovasc Dis 1996; 6 (suppl 2): 21.
146. Brott T, Broderick J, Barson W, et al. Continued bleeding during the first hours of intracerebral hemorrhage. Ann Neurol 1994; 36: 330.
147. Mendelow A. Mechanisms of ischemic brain damage with intracerebral hemorrhage. Stroke 1993; 24: I115-I117.
148. Nehls G, Major M, Mendelow D, et al. Experimental intracerebral hemorrhage: progression of hemodynamic changes after production of a spontaneous mass lesion. Neurosurg 1988; 23: 439-444.
149. Wagner K, Ghuhua X, Hua Y, et al. Lobar intracerebral hemorrhage model in pigs: Rapid edema development in perihematomal white matter. Stroke 1996; 27: 490-497.
150. Wagner K, Ghuhua X, Hua Y, et al. White matter edema in experimental lobar intracerebral hemorrhage. Stroke 1995; 26: 178.
151. Sills C, Villar-Cordova C, Pasteur W, et al. Demonstration of hypoperfusion surrounding intracerebral hematoma in Humans. Journal Stroke and Cerebrovas Dis 1996; 6: 17-24.